OPKO 1200

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:activeDuring various biomarkers
gptkbp:availability prescription only
gptkbp:clinicalTrials completed
Phase III
published in journals
follow guidelines
proven effective
improved diagnosis
monitoring health conditions
recommended by health authorities
gptkbp:collaborations various research institutions
gptkbp:community_service offered
gptkbp:communityOutreach conducted regularly
gptkbp:contraindication rare
none reported
gptkbp:customerFeedback considered in improvements
gptkbp:date FDA_approved
gptkbp:distributionChannels pharmacies
gptkbp:drugInterdiction minimal
gptkbp:educational_programs available online
gptkbp:formulation liquid
gptkbp:hasCompetitors other diagnostic tests
gptkbp:hasPopulation diverse demographics
gptkbp:healthcare available
monitored
provided by healthcare professionals
https://www.w3.org/2000/01/rdf-schema#label OPKO 1200
gptkbp:insuranceAccepted varies by plan
gptkbp:is_monitored_by regular check-ups
gptkbp:launchDate 2015
gptkbp:manufacturer gptkb:OPKO_Health,_Inc.
gptkbp:marketedAs gptkb:United_States
gptkbp:marketingStrategy direct-to-consumer
gptkbp:packaging vials
gptkbp:patentAssignee gptkb:OPKO_Health,_Inc.
gptkbp:priceRange varies by location
gptkbp:productionCompany marketed
gptkbp:publications peer-reviewed articles
gptkbp:regulatoryBody gptkb:FDA
gptkbp:regulatoryCompliance ensured
gptkbp:research private and public sources
gptkbp:research_areas oncology
gptkbp:researchInterest ongoing
with universities
gptkbp:route injection
gptkbp:safetyFeatures ongoing
generally safe
gptkbp:shelfLife 24 months
gptkbp:sideEffect mild reactions
gptkbp:storage room temperature
gptkbp:supplyChain managed_by_OPKO_Health.
gptkbp:targets adults
gptkbp:type diagnostic test
gptkbp:usedFor detecting diseases
gptkbp:userReviews generally positive